Comment on “angiotensin‐converting‐enzyme 2 inhibits liver fibrosis in mice”
Michael G. Lenos, Sofia‐Maria Tsaniklidou – 25 January 2010
Prevention of de novo hepatitis B virus infections: More seems no better
David Mutimer – 21 January 2010
Human leukocyte antigen antibodies in liver retransplantation
Adriana Zeevi, John G. Lunz – 21 January 2010
Pretransplant cryptococcosis and outcome after liver transplantation
Costi D. Sifri, Hsin‐Yun Sun, Thomas V. Cacciarelli, Brian Wispelwey, Timothy L. Pruett, Nina Singh – 21 January 2010 – The posttransplant outcomes and optimal management of patients with end‐stage liver disease who develop cryptococcosis prior to transplantation have not been defined. We discuss these issues in the context of successful liver transplantation and pretransplant cryptococcal disease.
Long‐term efficacy of stent placement for treating inferior vena cava stenosis following liver transplantation
Jae Myeong Lee, Gi‐Young Ko, Kyu‐Bo Sung, Dong Il Gwon, Hyun‐Ki Yoon, Sung‐Gyu Lee – 21 January 2010 – The aims of this study were to evaluate both the efficacy of stent placement for treating inferior vena cava (IVC) stenosis and the patency of hepatic veins (HVs) following IVC stent placement. Fourteen hepatic transplant recipients underwent stent placement to treat IVC stenosis. The median interval between transplantation and stent placement was 32 days. Stents varied from 20‐36 mm in diameter and were 60‐120 mm long.
Usefulness of the Kyoto criteria as selection criteria for living donor liver transplantation for hepatocellular carcinoma
Toshimi Kaido, Yasutsugu Takada, Shinji Uemoto – 15 January 2010
Poor outcome after liver transplantation for transthyretin amyloid neuropathy in a family with an Ala36Pro transthyretin mutation: Case report
Kate R. Muller, Robert Padbury, Gary P. Jeffrey, Nicola K. Poplawski, Philip Thompson, Anne Tonkin, Hugh A. J. Harley – 15 January 2010 – Transthyretin amyloid polyneuropathy, caused by mutations in the transthyretin gene, is a progressive condition for which liver transplantation is an established treatment. Favorable outcomes have been described in patients with the most common transthyretin mutation, Val30Met, but outcomes have been variable in patients with other mutations.
Predictors of graft and patient survival in subjects undergoing transplantation for hepatitis C virus infection
Vinod K. Audimoolam, Mathew R. Foxton, Kosh Agarwal, John G. O'Grady, Michael A. Heneghan – 15 January 2010
Can children catch up in growth after living donor liver transplantation?
Walid Mohamed El Moghazy, Yasuhiro Ogura, Kouji Harada, Akio Koizumi, Shinji Uemoto – 15 January 2010 – Several studies have shown improved growth after liver transplantation, but long‐term follow‐up data have been lacking. This study was aimed at evaluating the ability of children to catch up in height after living donor liver transplantation (LDLT) and at clarifying factors affecting growth. Growth was assessed by serial height measurements performed during follow‐up.